About TeloiX

What TeloiX is

TeloiX is a reference site built around a mechanism–intervention–study graph for telomere biology (telomere attrition, telomerase, shelterin, the Hayflick limit, ALT) and the interventions claimed to lengthen telomeres or activate telomerase. It is deliberately narrow: a small number of landmark interventions and studies, each fully sourced and honestly qualified, rather than a broad advice article. It reports what each study actually measured — telomere length? telomerase activity? a clinical outcome? — in which population. Telomere-driven replicative senescence is cross-referenced to the senesiq cluster, not duplicated.

The central honesty facts

No telomere intervention has a healthy-aging human lifespan randomized controlled trial. The human evidence here is real but qualified: a telomere-length biomarker RCT (TA-65), clinical outcomes in a rare telomere disease (danazol, nandrolone), and a small cancer-cohort pilot (Ornish). Beyond that, two truths govern every page: telomere length is a contested aging biomarker (longer is not simply healthier), and telomerase activation is not risk-free — the only FDA-approved telomerase drug, imetelstat (2024), inhibits telomerase to treat cancer, the opposite direction from anti-aging "activation."

Commercial conflict-of-interest note

The most-cited human "telomerase activator" data on this site — the TA-65 telomere-length RCT (Salvador 2016) and the earlier immune study (Harley 2011) — were produced by authors with a direct commercial interest in the product. TA-65 is sold by T.A. Sciences; Calvin Harley (a TA-65 co-inventor and long-time commercial proponent) and other T.A. Sciences–affiliated authors appear on those papers. This does not by itself invalidate the results, but it is a material conflict of interest that a reader weighing a supplement marketed on telomere claims must know. TeloiX has no commercial relationship with T.A. Sciences or any product mentioned.

Publisher / editorial identity

Nabus Research is the editorial owner and publisher. This site does not attribute content to any named individual author or reviewer; no person is fabricated for E-E-A-T purposes. When a named, verifiable human reviewer is assigned to a page in a future revision, that attribution will be added — and not before.

Sourcing standard

Every study record carries five visible qualifiers: species/population; exposure, route and schedule; comparator and duration; endpoint and numeric result; and what the study did NOT establish. Every record carries a verification_status, and every trial/registry identifier a citation_status. Journal/volume/DOI were confirmed via Crossref and trial status via the ClinicalTrials.gov v2 API where an identifier was resolvable; where an exact NCT/PMID/DOI was not confirmed against the primary record, it is marked needs_primary_fulltext rather than presented as verified — see the methodology page.

Monetization

Monetization is off in v1. No affiliate links, no sponsored placements, no ads.txt. This is a reference resource, not a shopping guide.

Prohibited claim language

The editorial process blocks a fixed list of prohibited marketing phrases — for example, claims that lengthening telomeres turns back your biological clock, that a supplement is a telomerase ‘fountain of youth’, that telomerase activation is risk-free, or that any compound here has a proven human lifespan effect — via an automated pattern check run at build time. See generators/check_claim_patterns.py.

Licensing & data enquiries

The structured telomere evidence dataset behind this site is independently sourced. For dataset-licensing or research-data enquiries, use the form below. This is an inbound enquiry channel only — no advertising, affiliate links, or sponsored placements appear on this site.

Version history